BCM
SMMT icon

Bayesian Capital Management’s Summit Therapeutics SMMT Stock Holding History

Bayesian Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-67,039
Closed -$1.2M – 933
2024
Q4 		$1.2M Buy
+67,039
New +$1.3M 0.15% 204
2024
Q3 		– Sell
-16,499
Closed -$129K – 1013
2024
Q2 		$129K Buy
+16,499
New +$89.1K 0.01% 643

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bayesian Capital Management's SMMT Position: Q1 2025 in Review

Bayesian Capital Management sold out of Summit Therapeutics (SMMT) in Q1 2025, closing a stake of 67,039 shares — an estimated $1.2M sold.

Bayesian Capital Management first reported a position in SMMT in Q2 2024 and held it in 2 quarters. The position peaked at $1.2M in Q4 2024. 212 funds tracked by Wall St. Rank hold SMMT as of Q1 2025.

  • Bayesian Capital Management reported no remaining Summit Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 67,039 Summit Therapeutics shares in Q1 2025, an estimated $1.2M.
  • Bayesian Capital Management first reported a position in Summit Therapeutics in Q2 2024 and held it in 2 quarters.
  • Bayesian Capital Management's Summit Therapeutics position peaked at $1.2M in Q4 2024.
  • 212 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.